Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent;~* Pregnant women at ≥ 36 weeks 0 days inclusive gestation;~* Women aged 18 years or older;~* Candidate for pharmacological induction of labor;~* Single, live vertex fetus;~* Baseline modified Bishop score ≤ 4;~* Parity ≤ 3 (parity is defined as one or more births live or dead after 24 weeks gestation);~* Body Mass Index (BMI) ≤ 50 at the time of entry to the study.~Exclusion Criteria:~* Women in active labor;~* Presence of uterine or cervical scar or uterine abnormality e.g., bicornate uterus. Biopsies, including cone biopsy of the cervix, are permitted;~* Administration of oxytocin or any cervical ripening or labor inducing agents (including mechanical methods) or a tocolytic drug within 7 days prior to enrollment. Magnesium sulfate is permitted if prescribed as treatment for pre-eclampsia or gestational hypertension;~* Severe pre-eclampsia marked by Hemolytic anemia, Elevated Liver enzymes, Low Platelet count (HELLP) syndrome, other end-organ affliction or Central Nervous System (CNS) findings other than mild headache;~* Fetal malpresentation;~* Diagnosed congenital anomalies, not including polydactyly;~* Any evidence of fetal compromise at baseline (e.g., non-reassuring fetal heart rate pattern or meconium staining);~* Amnioinfusion or other treatment of non-reassuring fetal status at any time prior to the induction attempt;~* Ruptured membranes ≥ 48 hours prior to the start of treatment;~* Suspected chorioamnionitis;~* Fever (oral or aural temperature \> 37.5°C);~* Any condition in which vaginal delivery is contraindicated e.g., placenta previa or any unexplained genital bleeding at any time after 24 weeks during this pregnancy;~* Known or suspected allergy to misoprostol, dinoprostone, other prostaglandins or any of the excipients;~* Any condition urgently requiring delivery;~* Unable to comply with the protocol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MVI 200 (Type: EXPERIMENTAL): MVI 200 mcg vaginal insert
- Dinoprostone Vaginal Insert (DVI) (Type: ACTIVE_COMPARATOR): 10 mg Dinoprostone vaginal insert

Based on this trial design, predict the completion outcome and termination type (if applicable).